Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy

NCT01195649 · clinicaltrials.gov ↗

TERMINATED

Status

11

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Renal Cell

Interventions

DRUG: Sorafenib (Nexavar, BAY43-9006)

Sponsor

Bayer